Generates Adjusted EBITDA of $3.6 million and EPS of $0.05 (CDN$0.61) Excluding legal provision EPS was $0.10 (CDN$0.12) OAKVILLE, ON, May 13, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH)...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced it will release its Q1 2021 financial results after market close on Thursday, May 13, 2021. The company will hold...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has received approval from the Toronto Stock Exchange ("TSX") to amend its normal course issuer bid...

Adjusted EBITDA increases 9% to $13.7 million and EPS increases 60% to $0.16 (CDN$0.211) for the full year OAKVILLE, ON, March 18, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q4 2020 financial results after the close on Thursday, March 18, 2021. The company will hold...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has entered into an exclusive co-promotion agreement (the "Agreement") with Verity Pharmaceuticals Inc. for...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has received an arbitration award in the previously announced dispute between the Company and Bausch Health...

Revenue Increases Sequentially to $4.9 million EBITDA2 was $2.7 million or 55% of net revenue OAKVILLE, ON, Nov. 12, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company")...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q3 2020 financial results after the close on Thursday, November 12, 2020. The Company will...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today the voting results for the election of directors at its Annual Meeting of Shareholders held earlier today. A...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, a Notice of Intention to Make a...

Income before taxes increased 36% to $2.5 million EBITDA increased 22% to $2.9 million Excluding a one-time tax adjustment EPS was $0.07 (CDN$0.10) OAKVILLE, ON, Aug. 12, 2020 /CNW/ - Cipher...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q2 2020 financial results after the close on Wednesday, August 12, 2020. The Company will...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") is pleased to announce that it has appointed seasoned Financial Executive Scott Langille as its new Chief Financial Officer...

Earnings per common share increases to $0.10 ($0.13 in Canadian Dollars1) OAKVILLE, ON, May 7, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced it will release its Q1 2020 financial results on Thursday, May 7, 2020. The company will hold a conference call on...

Adjusted EBITDA reaches $4.2 million and Net income increases to $2.6 million in the fourth quarter OAKVILLE, ON, March 25, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 2020 financial results conference call on Thursday, March 26, 2019. CONFERENCE CALL DETAILS...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") is pleased to announce that Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), the Company's U.S. marketing partner for...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the Company received a Notice of Termination (the "Notice") from Bausch Health in connection with the License,...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three and nine months ended September 30, 2019. Unless otherwise...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the details of its Q3 2019 financial results conference call on Thursday, November 7, 2019. CONFERENCE CALL...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has received Health Canada approval, on October 10, 2019, for TRULANCE® (plecanatide), a Guanylate cyclase-C...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three months ended June 30, 2019. Unless otherwise noted, all figures...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q2 2019 financial results conference call on Friday, August 9, 2019. CONFERENCE CALL DETAILS DATE:

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Mr. Craig Mull has been named Interim Chief Executive Officer of Cipher, replacing Robert Tessarolo. The...

MISSISSAUGA, Ontario, June 12, 2019 (GLOBE NEWSWIRE) -- Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced today...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three months ended March 31st, 2019. Unless otherwise noted, all...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2019 financial results conference call on Friday, May 10, 2019. The call will be hosted by...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Mr. Craig Mull was appointed as a member of the Company's Board of Directors, effective immediately. Mr....

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Stephen Lemieux, Chief Financial Officer and Secretary of Cipher has resigned to pursue other career...

Canadian product revenue increased 30% to $6.9 million for the year Completed six (6) strategic business transactions enhancing long-term value OAKVILLE, ON, March 19, 2019 /CNW/ - Cipher...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 2018 financial results conference call on Tuesday, March 19, 2019. The call will be hosted...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced that its New Drug Submission ("NDS") for A-101 40% topical solution ("A-101 40%") for the treatment of raised seborrheic keratoses ("SKs") has...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced that its New Drug Submission ("NDS") for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it will host a webcast investor presentation on Tuesday, December 11th at 11:00 AM ET. During the webcast,...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that pharmaceutical industry commercial executive, Michael Milloy, has joined the Company in the position of Vice...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three and nine months ended September 30th, 2018. Unless otherwise...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the details of its Q3 2018 financial results conference call on Wednesday, November 7, 2018. The call will be...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Canadian launch of Brinavess® (vernakalant hydrochloride) for the rapid conversion of recent onset atrial fibrillation ("AF"), (an...

Transaction broadens Cipher's Canadian portfolio providing entry into rapidly growing market MISSISSAUGA,ON, Sept. 18, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it received Health Canada approval of Xydalba™ (dalbavancin hydrochloride), the first and only one-dose treatment option for acute bacterial...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and six months ended June 30, 2018. Unless otherwise noted,...

Agreement expanded to include a portfolio of novel isotretinoin products New portfolio royalty extends through December 2024 MISSISSAUGA, ON, July 30, 2018 /CNW/ - Cipher Pharmaceuticals Inc....

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q2 2018 financial results conference call on Friday, August 10, 2018. The call will be hosted...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that pharmaceutical industry medical executive, Dr. Diane Gajewczyk, has joined the Company in the position of...

Effective May 15, 2018, the previously announced acquisition by Cipher Pharmaceuticals Inc. ("Cipher") of the Canadian business portfolio of Cardiome Pharma Corp. ("Cardiome") was completed by way...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has completed its previously announced strategic acquisition of the Canadian business portfolio of Cardiome Pharma Corp. (originally...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced today the voting results for the election of directors at its...

Company announces four transactions year to date adding revenue diversification and growth avenues in new therapeutic categories MISSISSAUGA, ON, May 10, 2018 /CNW/ - Cipher Pharmaceuticals Inc....